294 related articles for article (PubMed ID: 11286015)
1. Matrix metalloproteinases and bladder cancer.
Kanayama H
J Med Invest; 2001 Feb; 48(1-2):31-43. PubMed ID: 11286015
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
O-Charoenrat P; Rhys-Evans PH; Eccles SA
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in tumour invasion and metastasis.
Curran S; Murray GI
J Pathol; 1999 Nov; 189(3):300-8. PubMed ID: 10547590
[TBL] [Abstract][Full Text] [Related]
5. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
6. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
Hirano H; Tsuji M; Kizaki T; Sashikata T; Yoshi Y; Okada Y; Mori H
Med Electron Microsc; 2002 Mar; 35(1):16-23. PubMed ID: 12111403
[TBL] [Abstract][Full Text] [Related]
9. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
10. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
11. The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis.
Zhang D; Samani AA; Brodt P
Horm Metab Res; 2003; 35(11-12):802-8. PubMed ID: 14710361
[TBL] [Abstract][Full Text] [Related]
12. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Chang CC; Shieh GS; Wu P; Lin CC; Shiau AL; Wu CL
Cancer Res; 2008 Aug; 68(15):6281-91. PubMed ID: 18676852
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Bianco FJ; Gervasi DC; Tiguert R; Grignon DJ; Pontes JE; Crissman JD; Fridman R; Wood DP
Clin Cancer Res; 1998 Dec; 4(12):3011-6. PubMed ID: 9865914
[TBL] [Abstract][Full Text] [Related]
14. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
15. [Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract].
Piura B; Rabinovich A; Huleihel M
Harefuah; 2003 Nov; 142(11):786-91, 804. PubMed ID: 14631913
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
Wan Y; Wei Q; Pan Y; Liu Y
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):510-3. PubMed ID: 11832095
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
Gakiopoulou H; Nakopoulou L; Siatelis A; Mavrommatis I; Panayotopoulou EG; Tsirmpa I; Stravodimos C; Giannopoulos A
Clin Cancer Res; 2003 Nov; 9(15):5573-81. PubMed ID: 14654538
[TBL] [Abstract][Full Text] [Related]
18. [Matrix metalloproteinases and colorectal cancer].
Roeb E; Matern S
Med Klin (Munich); 2003 Dec; 98(12):763-70. PubMed ID: 14685678
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness.
Kader AK; Liu J; Shao L; Dinney CP; Lin J; Wang Y; Gu J; Grossman HB; Wu X
Clin Cancer Res; 2007 May; 13(9):2614-20. PubMed ID: 17473191
[TBL] [Abstract][Full Text] [Related]
20. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis.
Forget MA; Desrosiers RR; Béliveau R
Can J Physiol Pharmacol; 1999 Jul; 77(7):465-80. PubMed ID: 10535707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
